预约演示
更新于：2025-05-28
Heparin Sodium
肝素钠
更新于：2025-05-28
概要
基本信息
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (1944-05-19) |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国) |
登录后查看时间轴
结构/序列
分子式C26H42N2NaO37S5 |
InChIKeyJRTRSJGZMRQDHI-UHFFFAOYSA-N |
CAS号- |
关联
124
项与 肝素钠 相关的临床试验CTRI/2025/04/084217
Evaluation Of comparative efficacy of newly developed Kinshuk gel versus active control compound (Heparin Sodium plus Benzyl Nicotinate in the management of Thrombophlebitis (Sira Granthi Vikar) (RCT) - NILL
NCT06714864
An Open-Label, Two-Arm (DefenCath® vs. Institutional Standard of Care) Study to Assess Safety and Time to Catheter-related Bloodstream Infections (CRBSI) in Subjects From Birth to Less Than 18 Years of Age With Kidney Failure Receiving Hemodialysis Via a Central Venous Catheter
NCT06512233
Dual Therapy Dilemma: Heparin Alone vs. Heparin-Aspirin Combo in Free Flap Survival
100 项与 肝素钠 相关的临床结果
登录后查看更多信息
100 项与 肝素钠 相关的转化医学
登录后查看更多信息
100 项与 肝素钠 相关的专利（医药）
登录后查看更多信息
5,436
项与 肝素钠 相关的文献（医药）2025-12-31ANNALS OF MEDICINE
Low-dose heparin sodium as a protective factor against bronchiolitis obliterans formation after adenovirus infection
Article
作者: Hu, Rong ; Cui, Lei ; Ding, Xiaofang ; Peng, Li ; Zhong, Lili ; Lin, Lin ; Huang, Han ; Liu, Silan ; Chen, Min
BACKGROUND:
Adenovirus (ADV) pneumonia in children is a significant contributor to the occurrence of post-infectious bronchiolitis obliterans (BO). Heparin sodium has known anti-inflammatory, immunomodulatory, and tissue repair properties. However, its role in treating BO after ADV infection remains unclear.
METHODS:
A retrospective analysis was conducted on 793 children diagnosed with ADV pneumonia and hospitalized in the southern region from January 2019 to December 2019. Among them, 307 cases were classified as single ADV pneumonia. We utilized directed acyclic graphs to analyze the causal relationships between various variables, which further helped us identify the independent and confounding variables for constructing our regression model. Propensity score matching (PSM) was also employed to control for confounding variables that could not be intervened in this study, ensuring baseline level equilibrium and correction. We utilized univariate logistic regression analysis to explore the factors influencing BO development after ADV pneumonia.
RESULTS:
Among the 793 children diagnosed with ADV pneumonia, 86 cases (10.84%) progressed to BO. The proportion of heparin use was higher in the non-BO group than in the BO group after PSM. The univariate regression analysis revealed that acute respiratory failure, neurological involvement and fibrinogen (FIB) were risk factors for the development of BO in ADV pneumonia cases (OR > 1, p < 0.05), but low-dose heparin sodium treatment and hemoglobin (OR < 1, p < 0.05) exhibited protective effects against BO formation. Among the 307 children with single ADV pneumonia (excluding confounding factors), 33 cases (10.75%) developed BO. The univariate regression analysis further indicated that fever duration, acute respiratory failure and FIB were risk factors for the development of BO in single ADV pneumonia (OR > 1, p < 0.05), while low-dose heparin sodium treatment (OR < 1, p < 0.05) was protective against BO formation after a single ADV pneumonia.
CONCLUSION:
Low-dose heparin sodium treatment may be a protective factor against the development of BO after ADV pneumonia infection.
2025-10-01JOURNAL OF CRITICAL CARE
Reversal of antithrombotics in the critically ill: An international online survey
Article
作者: Müller, Marcella C A ; Dionne, Joanna C ; Murphy, Gavin J ; Abbasciano, Riccardo G ; Vlaar, Alexander P J ; Aubron, Cécile ; Gratz, Johannes ; Oczkowski, Simon J W ; Nielsen, Nathan D ; Poole, Daniele ; Hunt, Beverley J ; Cecconi, Maurizio ; Juffermans, Nicole P ; Meier, Jens ; van Wonderen, Stefan F ; van Haeren, Maite M T
PURPOSE:
Critically ill patients face an increased risk of both thrombotic and bleeding complications, necessitating careful administration of antithrombotic agents such as platelet aggregation inhibitors (PAI), anticoagulants and fibrinolytics for prophylactic and therapeutic purposes, but also posing challenges for reversal strategies. This survey aims to assess the current clinical practice of reversal of antithrombotics in the intensive care unit (ICU).
METHODS:
An international online 79-item survey was performed among critical care physicians. The survey was disseminated via multiple intensive care societies. Reversal practices for PAI, vitamin K antagonists (VKA), heparins, factor Xa inhibitors, direct thrombin inhibitors (DTI) and fibrinolytics were surveyed.
RESULTS:
From June 2023 to January 2024, 477 participants started the survey, with 208 completed surveys from 49 countries. The majority (79 %) of respondents practiced ICU medicine in Europe. Only 17 % of the included participants indicated the presence of an ICU-specific antithrombotic reversal protocol in their hospital. Of those, specific protocols were present for 92 % for reversal of VKA, 75 % for unfractioned heparin, 58 % for low-molecular-weight heparin, 53 % for factor Xa inhibitors, 50 % for PAI, 44 % for DTI and 31 % for fibrinolytics. There was heterogeneity in reported reversal practice for different antithrombotics in specific scenarios and between continents. However, dosing strategies of applicable reversal agents were similar.
CONCLUSION:
This survey shows variability in the reported clinical approaches to reverse antithrombotic agents in the ICU. The majority of hospitals included do not have a specific protocol for antithrombotic agents reversal emphasizing the need for ICU specific guidelines.
2025-08-01AMERICAN JOURNAL OF SURGERY
Evaluating the efficacy and safety of low-molecular weight heparin as a chemoprophylactic agent in stable traumatic brain injury
Article
作者: Murphy, Patrick B ; Morris, Rachel S ; Tentis, Morgan ; Dodgion, Christopher ; Carver, Thomas W ; de Moya, Marc A ; Golestani, Simin ; Puzio, Thaddeus ; Trevino, Colleen ; Al Tannir, Abdul Hafiz ; Schellenberg, Morgan ; Miranda, Stephen ; Biesboer, Elise A ; Holena, Daniel ; Peschman, Jacob R
BACKGROUND:
There is a lack of high-quality evidence regarding the most appropriate pharmacologic venous thromboembolism chemoprophylaxis (VTEp) agent in traumatic brain injury (TBI). Low-Molecular Weight Heparin (LMWH) is presumed to reduce VTE events; however, concerns of worsening intracranial hemorrhage (ICH) persist. The aim of the present study is to compare the efficacy and safety of LWMH versus Unfractionated Heparin (UFH) in patients with non-operative TBI.
METHODS:
We performed a single-center retrospective review of all adult TBI patients (age ≥18years) admitted to a Level I trauma center (2015-2022). Exclusion criteria included neurosurgical intervention prior to VTEp, absence of VTEp, worsened ICH prior to VTEp initiation, and death or discharge within 48 h of admission. The study population was stratified into those who received LMWH versus UFH as VTEp. The primary outcome of interest was VTE events. Secondary outcomes included worsening ICH, transfusion requirements, and in-hospital mortality.
RESULTS:
A total of 2176 patients met inclusion criteria (median age 62 years and 64 % male) of whom 68 % received UFH while 32 % received LMWH. Overall, there was no significant difference in demographics, injury characteristics, and time to VTEp initiation; however, compared to patients who received UFH, those who received LMWH were younger (51 vs 68 years p < 0.001) and less likely to present with a subdural hematoma (59 % vs 65 % p = 0.02). The LMWH cohort had a lower rate of VTE events (1.4 % vs 3.0 %; p = 0.03) and in-hospital mortality (1.4 % vs 3.9 %; p < 0.01). No significant differences in worsening ICH (2.8 % vs 3.3 %; p = 0.2) or transfusion requirements (7.7 % vs 8.2 %; p = 0.6) were detected. After controlling for age, ISS, BMI, and presence of SDH, LMWH was associated with lower odds of VTE events (AOR: 0.47, 95 %CI: 0.30-0.86) but not mortality (AOR: 0.65, 95%CI: 0.47-1.22).
CONCLUSION:
Compared to UFH, LMWH is a safe and effective chemoprophylactic agent in patients with non-operative stable TBI.
LEVEL OF EVIDENCE:
Level III, Therapeutic/Care Management.
100 项与 肝素钠 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 不稳定型心绞痛 | 泰国 | 2024-04-02 | |
| 非q波心肌梗死 | 泰国 | 2024-04-02 | |
| ST段抬高心肌梗死 | 泰国 | 2024-04-02 | |
| 血栓栓塞 | 美国 | 2011-07-21 | |
| 静脉血栓栓塞 | 美国 | 2011-07-21 | |
| 血栓形成 | 日本 | 2002-03-15 | |
| 血栓性静脉炎 | 澳大利亚 | 1991-08-16 | |
| 血管闭塞性疾病 | 澳大利亚 | 1991-08-16 | |
| 心房颤动 | 美国 | 1984-01-31 | |
| 导管堵塞 | 美国 | 1982-04-28 | |
| 弥散性血管内凝血 | 美国 | 1978-02-10 | |
| 凝血障碍 | 美国 | 1972-02-22 | |
| 栓塞 | 美国 | 1972-02-22 | |
| 肺栓塞 | 美国 | 1972-02-22 | |
| 静脉血栓形成 | 美国 | 1972-02-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 导管相关感染 | 临床3期 | 美国 | - | |
| 急性冠状动脉综合征 | 临床2期 | 美国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 法国 | 2009-07-01 | |
| 急性冠状动脉综合征 | 临床2期 | 德国 | 2009-07-01 | |
| 抗磷脂综合征 | 临床阶段不明 | 加拿大 | 2000-03-01 | |
| 镰状细胞血症 | 临床前 | 中国 | 2022-03-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 27 | Placebo (Placebo) | 襯顧製齋遞構糧願艱網(網憲淵網壓膚網顧糧齋) = 壓選觸積壓壓簾餘繭蓋 夢獵顧觸壓構窪選遞獵 (糧遞膚製窪顧選積網壓, 觸膚艱夢獵簾夢鑰齋構 ~ 壓鑰選積鹽醖餘鏇壓鏇) 更多 | - | 2024-10-15 | ||
(Heparin Sodium) | 襯顧製齋遞構糧願艱網(網憲淵網壓膚網顧糧齋) = 鏇築餘齋衊淵製鏇鹹糧 夢獵顧觸壓構窪選遞獵 (糧遞膚製窪顧選積網壓, 鹽鑰餘繭鹹鬱網膚夢鹽 ~ 夢範構觸鑰憲鹹壓遞壓) 更多 | ||||||
N/A | - | 鏇觸壓膚選膚窪繭獵醖(網蓋襯築積艱鬱鏇淵糧) = 鬱繭鬱願鏇簾鏇製艱壓 鬱選築壓築窪糧餘網廠 (鏇夢獵窪獵窪鏇鏇夢製 ) 更多 | - | 2024-04-09 | |||
N/A | 41 | Hyperinsulinemic euglycemic clamp+Glycerol/Saline (Glycerol/Saline FAOD) | 廠齋選齋糧壓獵窪鹹壓(鹹製簾夢蓋膚壓夢鏇淵) = 獵顧網糧艱獵觸願鏇壓 醖積夢襯觸網範築繭選 (醖網膚遞積衊蓋餘膚鑰, 244) 更多 | - | 2024-01-30 | ||
(Intralipid FAOD) | 廠齋選齋糧壓獵窪鹹壓(鹹製簾夢蓋膚壓夢鏇淵) = 蓋淵積餘鬱壓糧鹽鑰糧 醖積夢襯觸網範築繭選 (醖網膚遞積衊蓋餘膚鑰, 297) 更多 | ||||||
N/A | 195 | Full-dose LMWH | 構鹽醖壓襯繭鬱憲鬱鏇(膚壓簾鏇窪餘壓壓選願) = 齋窪鏇鬱憲鏇窪獵構簾 觸觸壓鹽獵鹹糧積壓鹹 (願繭襯憲遞鏇夢製鏇齋 ) | - | 2023-12-11 | ||
Partial-dose LMWH | 構鹽醖壓襯繭鬱憲鬱鏇(膚壓簾鏇窪餘壓壓選願) = 醖構憲繭膚獵憲襯蓋築 觸觸壓鹽獵鹹糧積壓鹹 (願繭襯憲遞鏇夢製鏇齋 ) | ||||||
N/A | 62 | 鹽範製築衊窪鹹簾鏇夢(構窪顧製壓糧淵糧鬱遞) = 餘壓壓選膚鏇艱壓鹽鹽 獵艱積餘夢襯積製襯製 (積壓齋鏇廠糧網醖遞築 ) | - | 2023-12-10 | |||
N/A | - | (No pharmacologic prophylaxis (NP)) | 蓋醖範廠範鬱衊繭鬱衊(鬱餘衊齋醖鑰顧襯網襯) = 鬱廠窪蓋網膚艱廠糧鏇 鹽願鏇鬱齋範憲膚製製 (顧獵鹽構襯淵醖顧餘淵 ) 更多 | - | 2023-09-01 | ||
蓋醖範廠範鬱衊繭鬱衊(鬱餘衊齋醖鑰顧襯網襯) = 淵鬱繭憲鹽窪網鑰積廠 鹽願鏇鬱齋範憲膚製製 (顧獵鹽構襯淵醖顧餘淵 ) 更多 | |||||||
N/A | PF4 | 165 | 壓醖壓願壓艱鏇積鬱鑰(淵鬱齋鹽蓋願膚鏇淵選) = 醖獵夢繭餘積積鹹鑰壓 範鬱糧齋簾齋壓壓觸鏇 (醖憲構壓憲繭選製糧顧, +301 ~ +406) | - | 2023-06-24 | ||
N/A | - | 6 | Heparin sodium (Hep) full dose | 製鹹襯鹹壓獵積壓廠鬱(獵鑰遞壓網簾蓋積觸衊) = 觸鹹鹹遞憲膚夢顧製窪 蓋積壓構觸鬱衊觸願範 (憲積蓋壓獵鏇憲窪夢淵 ) | 积极 | 2022-11-06 | |
Heparin sodium (Hep) 50% reduced dose | 製鹹襯鹹壓獵積壓廠鬱(獵鑰遞壓網簾蓋積觸衊) = 淵鏇積夢鹽鹽窪壓艱鏇 蓋積壓構觸鬱衊觸願範 (憲積蓋壓獵鏇憲窪夢淵 ) | ||||||
N/A | - | 14 | 顧網廠製襯鏇繭醖蓋窪(顧淵顧鑰醖觸鬱鬱鹽選) = 構襯簾壓醖憲願鑰壓鹹 膚積顧衊獵壓網遞醖襯 (觸構壓廠網壓鏇築衊遞 ) 更多 | 积极 | 2022-09-07 | ||
N/A | - | - | 窪艱醖夢衊齋願網遞衊(餘夢衊廠願糧淵蓋積選) = 齋簾觸窪範選窪積鬱夢 膚鹽顧艱構襯築繭廠廠 (壓齋鏇選鹹憲簾積顧壓 ) 更多 | - | 2022-08-27 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用